Lawrence Panasci

5.5k total citations · 1 hit paper
113 papers, 4.1k citations indexed

About

Lawrence Panasci is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Lawrence Panasci has authored 113 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 47 papers in Oncology and 25 papers in Genetics. Recurrent topics in Lawrence Panasci's work include DNA Repair Mechanisms (29 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Cancer Treatment and Pharmacology (12 papers). Lawrence Panasci is often cited by papers focused on DNA Repair Mechanisms (29 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Cancer Treatment and Pharmacology (12 papers). Lawrence Panasci collaborates with scholars based in Canada, United States and China. Lawrence Panasci's co-authors include Raquel Aloyz, Lilian Amrein, Areti Malapetsa, Michaël Pollak, Jonathan L. Bramson, Louis R. Bégin, David Davidson, J. H. Joncas, Georgios Christodoulopoulos and Mahvash Zakikhani and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Lawrence Panasci

109 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 384 citations Igor Bondarenko, Ekaterina Trishkina et al. profile →

Peers

Lawrence Panasci

ONCOL

PRM

GENET

Anderson J. Ryan United Kingdom

Timothy E. Kute United States

Young E. Whang United States

Dvorit Samid United States

Jill Kolesar United States

Stefania Scala Italy

Rena G. Lapidus United States

T.R. Jeffry Evans United Kingdom

Tona M. Gilmer United States

Norma O’Donovan Ireland

Anderson J. Ryan United Kingdom

Lawrence Panasci

2.9k ×1.5

ONCOL

3.9k ×2.0

1.5k ×1.5

1.4k ×1.7

PRM

450 ×0.7

GENET

Citations per year, relative to Lawrence Panasci Lawrence Panasci (= 1×) peers Anderson J. Ryan

Countries citing papers authored by Lawrence Panasci

Since Specialization

Citations

This map shows the geographic impact of Lawrence Panasci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Panasci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Panasci more than expected).

Fields of papers citing papers by Lawrence Panasci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Panasci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Panasci. The network helps show where Lawrence Panasci may publish in the future.

Co-authorship network of co-authors of Lawrence Panasci

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Panasci. A scholar is included among the top collaborators of Lawrence Panasci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Panasci. Lawrence Panasci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elkholi, Islam E., et al.. (2025). High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer. Clinical Breast Cancer. 25(6). e690–e696.e1. 1 indexed citations

Panasci, Lawrence, et al.. (2023). PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin. Frontiers in Bioscience-Landmark. 28(3). 52–52.

Assouline, Sarit, Lilian Amrein, Raquel Aloyz, et al.. (2020). IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 61(7). 1653–1659. 6 indexed citations

Ellis, Matthew J., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Annals of Oncology. 27. vi554–vi554. 10 indexed citations

Wang, Yunzhe, Alycia Noë, David Davidson, et al.. (2015). Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. Frontiers in Pharmacology. 6. 147–147. 18 indexed citations

Garg, Amit, et al.. (2014). Hormonal Manipulation with Letrozole in the Treatment of Metastatic Malignant pecoma. Current Oncology. 21(3). 518–520. 9 indexed citations

Davidson, David, Yunzhe Wang, Raquel Aloyz, & Lawrence Panasci. (2012). The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Investigational New Drugs. 31(2). 461–468. 49 indexed citations

Sahebjam, Solmaz, Raquel Aloyz, Dragana Pilavdzic, et al.. (2011). Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. British Journal of Cancer. 105(9). 1342–1345. 74 indexed citations

Amrein, Lilian, David Davidson, M. Shawi, et al.. (2011). Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. Leukemia Research. 35(8). 1080–1086. 13 indexed citations

10.

Ferrario, Cristiano, et al.. (2011). Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer. Journal of Chemotherapy. 23(1). 32–35. 4 indexed citations

11.

Amrein, Lilian, Cristiano Ferrario, James B. Johnston, et al.. (2008). Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. British Journal of Haematology. 143(5). 698–706. 49 indexed citations

12.

Loignon, Martin, et al.. (2005). Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis. Journal of Pharmacology and Experimental Therapeutics. 314(2). 495–505. 57 indexed citations

13.

Panasci, Lawrence & Moulay A. Alaoui‐Jamali. (2004). DNA Repair in Cancer Therapy. Humana Press eBooks. 13 indexed citations

14.

Aloyz, Raquel, et al.. (2002). Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochemical Pharmacology. 63(9). 1585–1588. 43 indexed citations

15.

Remack, Joanna S., et al.. (1999). Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.. PubMed. 5(12). 4186–90. 10 indexed citations

16.

Chen, Zhong-Ping, Areti Malapetsa, Daniela Di Marcantonio, et al.. (1997). Evidence for Nucleotide Excision Repair as a Modifying Factor ofO6-Methylguanine-DNA Methyltransferase-Mediated Innate Chloroethylnitrosourea Resistance in Human Tumor Cell Lines. Molecular Pharmacology. 52(5). 815–820. 36 indexed citations

17.

Bramson, Jonathan L. & Lawrence Panasci. (1995). Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-β-d-arabinofuranosylcytosine. Biochemical Pharmacology. 50(1). 131–135. 3 indexed citations

18.

Bramson, Jonathan L., et al.. (1995). Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. Mutation Research/DNA Repair. 336(3). 269–278. 39 indexed citations

19.

Bramson, Jonathan L., Timothy O’Connor, & Lawrence Panasci. (1995). Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents. Biochemical Pharmacology. 50(1). 39–44. 18 indexed citations

20.

Panasci, Lawrence, et al.. (1988). Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochemical Pharmacology. 37(16). 3189–3192. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact